Haematologica, Vol 92, Issue 7, 1000-1001 doi:10.3324/haematol.10943
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goranova-Marinova, V.
Right arrow Articles by Tzvetkova, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goranova-Marinova, V.
Right arrow Articles by Tzvetkova, T.

Multiple Myeloma

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations

Veselina Goranova-Marinova, Stefan Goranov, Pavel Pavlov*, Todorka Tzvetkova*

Clinic of Hematology, University Hospital "Sv.Georgi"-Plovdiv;
* Central Clinical Laboratory, University Hospital "Sv. Georgi", Plovdiv, Plovdiv, Bulgaria

Correspondence: Veselina Goranova-Marinova, Clinic of Hematology, University Hospital"Sv.Georgi"-Plovdiv, 15 A Vasil Aprilov blv, Plovdiv 4002, Bulgaria. Phone: international +359.32602481. Fax: international +359.32602481. E-mail: vesselina_goranova{at}yahoo.com

Serum levels of OPG and RANKL and their clinical correlations were analyzed in 66 newly–diagnosed patients with multiple myeloma (MM). RANKL and RANKL/OPG ratios were significantly increased in advanced clinical stages and high grade myeloma bone disease (MBD), while OPG showed a tendency to decrease. Renal failure modified the expression of OPG. RANKL and RANKL/OPG ratios are informative markers for myeloma tumor burden and MBD.




This article has been cited by other articles:


Home page
 IBMS BoneKEyHome page
M. K. Crook and T. A. Guise
RANKL: Targeting Bone and Cancer to Treat Skeletal Complications of Malignancy
IBMS BoneKEy, September 1, 2009; 6(9): 323 - 338.
[Abstract] [Full Text] [PDF]